Inc (NYSEAmerican:HEB) CEO Tom Equels tells Proactive Investors the Florida-based immunopharma company has shipped more than 300 recently manufactured vials of Ampligen to the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) clinical site at Incline Village, Nevada.
Equels says the vials will be used in the Expanded Access Program, authorized by the FDA to treat ME/CFS patients in an effort to expand compassionate care treatment to treat the disease where there is no commercially approved therapy.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc named herein, including the promotion by the Company of AIM ImmunoTech Inc in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HERE
